Beam Therapeutics (BEAM) Competitors $24.49 -0.80 (-3.16%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BEAM vs. NTLA, KYMR, REPL, SGMO, EDIT, RGEN, HALO, KRYS, ADMA, and ACLXShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Intellia Therapeutics (NTLA), Kymera Therapeutics (KYMR), Replimune Group (REPL), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Repligen (RGEN), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and Arcellx (ACLX). These companies are all part of the "medical" sector. Beam Therapeutics vs. Intellia Therapeutics Kymera Therapeutics Replimune Group Sangamo Therapeutics Editas Medicine Repligen Halozyme Therapeutics Krystal Biotech ADMA Biologics Arcellx Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment. Which has more volatility & risk, BEAM or NTLA? Beam Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Does the MarketBeat Community believe in BEAM or NTLA? Intellia Therapeutics received 384 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 69.27% of users gave Intellia Therapeutics an outperform vote while only 54.26% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes5154.26% Underperform Votes4345.74% Intellia TherapeuticsOutperform Votes43569.27% Underperform Votes19330.73% Which has stronger valuation & earnings, BEAM or NTLA? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$377.71M5.37-$132.53M-$1.76-13.91Intellia Therapeutics$36.28M36.83-$481.19M-$5.44-2.41 Do analysts prefer BEAM or NTLA? Beam Therapeutics presently has a consensus target price of $44.91, suggesting a potential upside of 83.38%. Intellia Therapeutics has a consensus target price of $54.94, suggesting a potential upside of 318.73%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72 Is BEAM or NTLA more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -41.07%. Beam Therapeutics' return on equity of -16.22% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% Intellia Therapeutics N/A -49.34%-40.27% Does the media refer more to BEAM or NTLA? In the previous week, Intellia Therapeutics had 20 more articles in the media than Beam Therapeutics. MarketBeat recorded 24 mentions for Intellia Therapeutics and 4 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.58 beat Intellia Therapeutics' score of 0.51 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 6 Very Positive mention(s) 8 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in BEAM or NTLA? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBeam Therapeutics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.03B$2.93B$5.03B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E Ratio-13.9146.01135.4117.82Price / Sales5.37360.241,160.9774.56Price / CashN/A160.0933.5332.53Price / Book2.033.734.674.68Net Income-$132.53M-$41.63M$119.07M$226.08M7 Day Performance-6.92%-4.73%-1.83%-1.04%1 Month Performance5.79%-6.53%-3.60%1.04%1 Year Performance-12.38%25.63%31.66%26.28% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics2.9185 of 5 stars$24.49-3.2%$44.91+83.4%-20.4%$2.03B$377.71M-13.91461NTLAIntellia Therapeutics4.5389 of 5 stars$13.12-7.1%$54.94+318.7%-56.7%$1.44B$36.28M0.00600Analyst ForecastKYMRKymera Therapeutics1.4071 of 5 stars$44.05+2.8%$52.13+18.4%+110.9%$2.77B$78.59M0.00170Analyst ForecastREPLReplimune Group4.2366 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A0.00210SGMOSangamo Therapeutics2.1859 of 5 stars$1.95-0.5%$7.00+259.0%+369.9%$408.95M$176.23M0.00480Analyst RevisionGap UpEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$204.72M$78.12M0.00230Short Interest ↓RGENRepligen4.6331 of 5 stars$138.90+8.1%$190.25+37.0%-10.8%$7.20B$638.76M0.001,783Positive NewsHALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.70B$829.25M15.15390Analyst ForecastKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive NewsADMAADMA Biologics3.3139 of 5 stars$21.37+3.6%$21.25-0.6%+430.3%$5.05B$258.21M75.68530ACLXArcellx2.9241 of 5 stars$87.22-0.4%$103.08+18.2%+65.8%$4.72B$155.82M-122.85130Short Interest ↓ Related Companies and Tools Related Companies NTLA Alternatives KYMR Alternatives REPL Alternatives SGMO Alternatives EDIT Alternatives RGEN Alternatives HALO Alternatives KRYS Alternatives ADMA Alternatives ACLX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
